Bedel Financial Consulting’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.96M | Buy |
11,757
+9
| +0.1% | +$1.94K | 0.28% | 49 |
|
|
2026
Q1 | $2.56M | Buy |
11,748
+24
| +0.2% | +$5.32K | 0.29% | 49 |
|
|
2025
Q4 | $2.68M | Sell |
11,724
-873
| -7% | -$199K | 0.29% | 47 |
|
|
2025
Q3 | $2.92M | Buy |
12,597
+30
| +0.2% | +$6.11K | 0.37% | 37 |
|
|
2025
Q2 | $2.33M | Buy |
12,567
+23
| +0.2% | +$4.28K | 0.32% | 41 |
|
|
2025
Q1 | $2.35M | Buy |
12,544
+67
| +0.5% | +$13K | 0.34% | 38 |
|
|
2024
Q4 | $2.39M | Buy |
12,477
+175
| +1% | +$32.2K | 0.33% | 40 |
|
|
2024
Q3 | $2.43M | Buy |
12,302
+35
| +0.3% | +$6.53K | 0.34% | 35 |
|
|
2024
Q2 | $2.1M | Buy |
12,267
+18
| +0.1% | +$2.98K | 0.31% | 36 |
|
|
2024
Q1 | $2.23M | Sell |
12,249
-66
| -0.5% | -$11.4K | 0.35% | 35 |
|
|
2023
Q4 | $1.91M | Sell |
12,315
-314
| -2% | -$45.8K | 0.35% | 34 |
|
|
2023
Q3 | $1.88M | Buy |
12,629
+94
| +0.7% | +$13.8K | 0.38% | 32 |
|
|
2023
Q2 | $1.69M | Buy |
12,535
+153
| +1% | +$22.4K | 0.35% | 37 |
|
|
2023
Q1 | $1.97M | Sell |
12,382
-104
| -0.8% | -$15.9K | 0.48% | 27 |
|
|
2022
Q4 | $2.02M | Buy |
12,486
+291
| +2% | +$44.6K | 0.5% | 27 |
|
|
2022
Q3 | $1.81M | Buy |
12,195
+34
| +0.3% | +$4.88K | 0.48% | 25 |
|
|
2022
Q2 | $1.86M | Buy |
12,161
+197
| +2% | +$30.1K | 0.55% | 22 |
|
|
2022
Q1 | $1.94M | Buy |
11,964
+356
| +3% | +$51.7K | 0.61% | 18 |
|
|
2021
Q4 | $1.57M | Buy |
11,608
+494
| +4% | +$58.4K | 0.49% | 25 |
|
|
2021
Q3 | $1.2M | Buy |
11,114
+1,823
| +20% | +$208K | 0.41% | 32 |
|
|
2021
Q2 | $1.05M | Buy |
9,291
+546
| +6% | +$61.5K | 0.36% | 38 |
|
|
2021
Q1 | $946K | Buy |
8,745
+865
| +11% | +$92.5K | 0.37% | 39 |
|
|
2020
Q4 | $844K | Buy |
7,880
+525
| +7% | +$50.5K | 0.37% | 38 |
|
|
2020
Q3 | $644K | Sell |
7,355
-191
| -3% | -$18K | 0.32% | 50 |
|
|
2020
Q2 | $741K | Sell |
7,546
-619
| -8% | -$54.5K | 0.4% | 36 |
|
|
2020
Q1 | $622K | Buy |
8,165
+977
| +14% | +$83.2K | 0.41% | 34 |
|
|
2019
Q4 | $636K | Buy |
7,188
+1
| +0% | +$83 | 0.36% | 47 |
|
|
2019
Q3 | $544K | Sell |
7,187
-175
| -2% | -$12K | 0.33% | 58 |
|
|
2019
Q2 | $535K | Sell |
7,362
-108
| -1% | -$8.49K | 0.33% | 60 |
|
|
2019
Q1 | $602K | Buy |
7,470
+309
| +4% | +$25.3K | 0.38% | 45 |
|
|
2018
Q4 | $660K | Sell |
7,161
-235
| -3% | -$20.7K | 0.47% | 35 |
|
|
2018
Q3 | $679K | Buy |
7,396
+220
| +3% | +$20.9K | 0.45% | 41 |
|
|
2018
Q2 | $665K | Buy |
7,176
+2,235
| +45% | +$218K | 0.49% | 39 |
|
|
2018
Q1 | $468K | Sell |
4,941
-110
| -2% | -$12.1K | 0.36% | 57 |
|
|
2017
Q4 | $488K | Buy |
+5,051
| New | +$476K | 0.44% | 54 |
|
Other funds holding ABBV
ECSS
ATO
Bedel Financial Consulting's ABBV Position: Q2 2026 in Review
Bedel Financial Consulting increased its AbbVie (ABBV) stake by 0.08% in Q2 2026, buying an estimated $1.94K and bringing the position to 11,757 shares worth $2.96M. The position accounts for 0.28% of the portfolio, ranked #49.
Bedel Financial Consulting first reported a position in ABBV in Q4 2017 and has held it in 35 quarters since. 2,121 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Bedel Financial Consulting held 11,757 shares of AbbVie worth $2.96M as of Q2 2026.
- Bedel Financial Consulting bought 9 AbbVie shares in Q2 2026, an estimated $1.94K.
- AbbVie made up 0.28% of Bedel Financial Consulting's portfolio in Q2 2026, its #49 holding.
- Bedel Financial Consulting first reported a position in AbbVie in Q4 2017 and has held it in 35 quarters since.
- 2,121 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Bedel Financial Consulting's 13F filing for Q2 2026, filed 29 Jul 2026.